170 related articles for article (PubMed ID: 37690483)
1. The role and participation of immune cells in the endometrial tumor microenvironment.
Dey DK; Krause D; Rai R; Choudhary S; Dockery LE; Chandra V
Pharmacol Ther; 2023 Nov; 251():108526. PubMed ID: 37690483
[TBL] [Abstract][Full Text] [Related]
2. Bibliometric and visualized analysis of the top-100 highly cited articles on immunotherapy for endometrial cancer.
Zheng W; Wu Y; Wang Y; Cheng J; Shen W
Medicine (Baltimore); 2023 Jul; 102(27):e34228. PubMed ID: 37417594
[TBL] [Abstract][Full Text] [Related]
3. Identification of immunogenic cell death-related subtypes used for predicting survival and immunotherapy of endometrial carcinoma through a bioinformatics analysis.
Liu Z; Luo Y; Su L; Hu X
Medicine (Baltimore); 2023 Aug; 102(31):e34571. PubMed ID: 37543760
[TBL] [Abstract][Full Text] [Related]
4. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L; Harold J; Tymon-Rosario J; Santin AD
Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
[TBL] [Abstract][Full Text] [Related]
8. High-Grade Endometrial Stromal Sarcoma: Molecular Alterations and Potential Immunotherapeutic Strategies.
Kim Y; Kim D; Sung WJ; Hong J
Front Immunol; 2022; 13():837004. PubMed ID: 35242139
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic and immune-related gene signatures in the tumor microenvironment of endometrial cancer.
Wang G; Wang D; Sun M; Liu X; Yang Q
Int Immunopharmacol; 2020 Nov; 88():106931. PubMed ID: 32889237
[TBL] [Abstract][Full Text] [Related]
10. Immune check-point in endometrial cancer.
De Felice F; Marchetti C; Tombolini V; Panici PB
Int J Clin Oncol; 2019 Aug; 24(8):910-916. PubMed ID: 31049759
[TBL] [Abstract][Full Text] [Related]
11. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in endometrial cancer: new scenarios on the horizon.
Di Tucci C; Capone C; Galati G; Iacobelli V; Schiavi MC; Di Donato V; Muzii L; Panici PB
J Gynecol Oncol; 2019 May; 30(3):e46. PubMed ID: 30887763
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
[TBL] [Abstract][Full Text] [Related]
14. Facts and Hopes in Immunotherapy of Endometrial Cancer.
Marín-Jiménez JA; García-Mulero S; Matías-Guiu X; Piulats JM
Clin Cancer Res; 2022 Nov; 28(22):4849-4860. PubMed ID: 35789264
[TBL] [Abstract][Full Text] [Related]
15. The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
Xu J; Shi Q; Wang B; Ji T; Guo W; Ren T; Tang X
Front Immunol; 2023; 14():1257254. PubMed ID: 37720221
[TBL] [Abstract][Full Text] [Related]
16. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime.
Pradip D; Jennifer A; Nandini D
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502029
[TBL] [Abstract][Full Text] [Related]
17. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
18. The role of toll-like receptors (TLRs) and their therapeutic applications in endometrial cancer.
Arabian S; Boostan A; Darzi S
Clin Transl Oncol; 2023 Apr; 25(4):859-865. PubMed ID: 36374404
[TBL] [Abstract][Full Text] [Related]
19. Reanalysis of single-cell data reveals macrophage subsets associated with the immunotherapy response and prognosis of patients with endometrial cancer.
Wu Q; Jiang G; Sun Y; Li B
Exp Cell Res; 2023 Sep; 430(2):113736. PubMed ID: 37541419
[TBL] [Abstract][Full Text] [Related]
20. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
